Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer
- Madhavi NagillaAffiliated withSection of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Chicago
- , Rebecca L. BrownAffiliated withSection of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Chicago Email author
- , Ezra E. W. CohenAffiliated withSection of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Chicago
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Patients with advanced medullary thyroid cancer (MTC) have poor prognoses and limited treatment options. Improved knowledge about molecular aberrations associated with MTC and the availability of novel targeted tyrosine kinase inhibitors (TKIs) have led to new potential treatment modalities. Cabozantinib is an oral multitargeted TKI with activity against multiple receptors including RET, vascular endothelial growth factor receptor type 2 (VEGFR2), and MET that has been evaluated in MTC in the preclinical and clinical arenas.
This article reviews unmet clinical needs in advanced MTC. The authors consider novel agents that have been studied in MTC, with a focus on the investigational agent cabozantinib. Up-to-date clinical data of cabozantinib in MTC are discussed.
Recent clinical evaluation suggests that cabozantinib is the first agent to prolong progression-free survival in patients with progressive MTC. These findings indicate that cabozantinib may be an effective therapy in advanced MTC. No improvement in overall survival has been demonstrated but data are not mature.
Cabozantinib may be an effective treatment option for patients with advanced MTC and is worthy of further evaluation.
KeywordsCabozantinib Endocrinology Medullary thyroid cancer Oncology Targeted therapy Tyrosine kinase inhibitors
- Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer
Advances in Therapy
Volume 29, Issue 11 , pp 925-934
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare Communications
- Additional Links
- Medullary thyroid cancer
- Targeted therapy
- Tyrosine kinase inhibitors
- Industry Sectors